Vincenzo Libri is a Clinical Senior Lecturer within the Division of Investigative Science at Imperial College London and Head of Clinical Studies at the ‘Sir John McMichael’ Clinical Research Centre - Hammersmith Campus. He also coordinates a MRes in Translational Medicine for graduates in medicine and basic scientists with a degree in life sciences.
From 1990 to 1998 he was a Welcome Trust and Medical Research Council Grant Holder at the School of Pharmacy, University of London (UK). In 1994 he was appointed Lecturer in Clinical Pharmacology at the University of Rome, (Italy). In the last ten years, Vincenzo has worked in multiple Pharmaceutical Companies (GlaxoWellcome, Eli Lilly, and GlaxoSmithKline) undertaking direct responsibilities for phase I/II clinical trials. In 2004 he was appointed Head of Experimental and Translational Medicine at the Department of Clinical Pharmacology and Discovery Medicine, Neurology CEDD, GSK-UK.
Dr Libri joined Imperial College in April 2009 to lead a team of clinicians, nurses and administrative staff and coordinate the development of a sustainable portfolio of clinical trials and experimental medicine studies across therapeutic areas. He is a Principal Investigator for the development and implementation of Phase I/II clinical trials in healthy volunteers and patients, with primary interests in experimental neurology, translational medicine and clinical neuro-pharmacology.
et al., 2023, Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection, Lancet Infectious Diseases, Vol:23, ISSN:1473-3099, Pages:781-784
et al., 2023, Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial, Journal of Infection, Vol:87, ISSN:0163-4453, Pages:18-26
Turner P, 2023, Persistence of immune response in heterologous COVID vaccination schedules in the Com-COV2 study - a single-blind, randomised trial incorporating mRNA, viral-vector and protein-adjuvant vaccines, Journal of Infection, Vol:86, ISSN:0163-4453, Pages:574-583
et al., 2023, A double-blind, randomized, placebo-controlled trial of ursodeoxycholic Acid (UDCA) in Parkinson's disease, Movement Disorders, Vol:38, ISSN:0885-3185, Pages:1493-1502
et al., 2023, Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial (vol 84, pg 795, 2022), Journal of Infection, Vol:86, ISSN:0163-4453, Pages:540-541